Edgewise Therapeutics, Inc.
EWTX
Pozycja w akcjach
#3981
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Cena akcji
$38.12
Kapitalizacja rynkowa
$4.10B
Zmiana (1 dzień)
2.50%
Zmiana (1 rok)
153.12%
Kraj
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategoria
Healthcare
Historia stopy dywidendy dla Edgewise Therapeutics, Inc. (EWTX)
Stopa dywidendy (TTM) dla Edgewise Therapeutics, Inc. (symbol akcji: EWTX) na dzień 2023-12-31 wynosi: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Edgewise Therapeutics, Inc. (EWTX) od 2019 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
